A Phase II Clinical Trial of PM01183 in BRCA 1/2-Associated or Unselected Metastatic Breast Cancer
Pharmacokinetic Study of PM01183 in Combination With Irinotecan in Patients With Selected Solid Tumors
Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors
Study to Evaluate PM01183 in Combination With Olaparib in Advanced Solid Tumors
Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin (DOX) Versus Cyclophosphamide (CTX), Doxorubicin (DOX) and Vincristine (VCR) (CAV) or Topotecan as Treatment in Patients With Small-Cell Lung Cancer
† Study has passed its completion date and status has not been verified in more than two years.